NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
45 hedge funds and large institutions have $23.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 6 closing their positions.
273% more call options, than puts
Call options by funds: $56K | Put options by funds: $15K
0% more funds holding
Funds holding: 45 → 45 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
26% less capital invested
Capital invested by funds: $31.6M → $23.3M (-$8.32M)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$302K |
| 2 |
Renaissance Technologies
New York
|
+$160K |
| 3 |
WPW
Waldron Private Wealth
Bridgeville,
Pennsylvania
|
+$103K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$77.4K |
| 5 |
D.E. Shaw & Co
New York
|
+$64.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$528K |
| 2 |
FLC
Fifth Lane Capital
Austin,
Texas
|
-$56K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$51K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26.3K |
| 5 |
Two Sigma Advisers
New York
|
-$25.5K |
NBSE Hedge Fund Activity: Q1 2022 in Review
45 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2022, worth a combined $23.3M — down 26% from $31.6M a quarter earlier.
Fund positioning in NBSE was balanced in Q1 2022: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 12 trimmed.
The largest buyer was CM Management, adding an estimated $302K. The largest seller was Vanguard Group, cutting an estimated $528K.
- 45 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $23.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2022, down 26% quarter-over-quarter.
- 6 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2022 and 6 closed out, a net change of 0 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2022 was CM Management, an estimated $302K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2022 was Vanguard Group, an estimated $528K sold.
Based on aggregated 13F filings for Q1 2022.